European Journal of Internal Medicine
Volume 18, Issue 6 , Pages 474-483 , October 2007

Relation between plasma homocysteine, gene polymorphisms of homocysteine metabolism-related enzymes, and angiographically proven coronary artery disease

  • Abdelilah Laraqui

      Affiliations

    • Ligue Nationale de Lutte Contre les Maladies Cardiovasculaires, Unité d'Etudes des Facteurs Métaboliques et Polymorphismes Génétiques, Rabat, Morocco
    • UFR Biochimie Immunologie, Faculté des Sciences, Université Mohamed V. Rabat, Morocco
    • Laboratoire de Biochimie Médicale A, Unité Fonctionnelle Endocrinologie-Moléculaire-Oncologie, CHU Pitié-Salpêtrière, Paris, France
    • Corresponding Author InformationCorresponding author. Unité d'Etudes des Facteurs Métaboliques et Polymorphismes Génétiques, Ligue Nationale de Lutte Contre les Maladies Cardiovasculaires, BP 1326-Rabat R.P. 10000, Morocco. Tel.: +212 63 14 43 96; fax: +212 37 67 32 32.
    • ,
  • Abdellatif Allami

      Affiliations

    • Ligue Nationale de Lutte Contre les Maladies Cardiovasculaires, Unité d'Etudes des Facteurs Métaboliques et Polymorphismes Génétiques, Rabat, Morocco
    • UFR Biologie Cellulaire et Moléculaire, Faculté des Sciences, Université Abdelmalek Es-Saadi, Tétouan, Morocco
    • ,
  • Alain Carrié

      Affiliations

    • Laboratoire de Biochimie Médicale A, Unité Fonctionnelle Endocrinologie-Moléculaire-Oncologie, CHU Pitié-Salpêtrière, Paris, France
    • ,
  • Alain Raisonnier

      Affiliations

    • Laboratoire de Biochimie Médicale A, Unité Fonctionnelle Endocrinologie-Moléculaire-Oncologie, CHU Pitié-Salpêtrière, Paris, France
    • ,
  • Anne-Sofie Coiffard

      Affiliations

    • Laboratoire de Biochimie Médicale A, Unité Fonctionnelle Endocrinologie-Moléculaire-Oncologie, CHU Pitié-Salpêtrière, Paris, France
    • ,
  • Fatima Benkouka

      Affiliations

    • UFR Biochimie Immunologie, Faculté des Sciences, Université Mohamed V. Rabat, Morocco
    • ,
  • Abdenabi Bendriss

      Affiliations

    • UFR Biologie Cellulaire et Moléculaire, Faculté des Sciences, Université Abdelmalek Es-Saadi, Tétouan, Morocco
    • ,
  • Abdelaziz Benjouad

      Affiliations

    • UFR Biochimie Immunologie, Faculté des Sciences, Université Mohamed V. Rabat, Morocco
    • ,
  • N. Bennouar

      Affiliations

    • Ligue Nationale de Lutte Contre les Maladies Cardiovasculaires, Unité d'Etudes des Facteurs Métaboliques et Polymorphismes Génétiques, Rabat, Morocco
    • ,
  • Nizar El Kadiri

      Affiliations

    • Ligue Nationale de Lutte Contre les Maladies Cardiovasculaires, Unité d'Etudes des Facteurs Métaboliques et Polymorphismes Génétiques, Rabat, Morocco
    • ,
  • Anwar Benomar

      Affiliations

    • Ligue Nationale de Lutte Contre les Maladies Cardiovasculaires, Unité d'Etudes des Facteurs Métaboliques et Polymorphismes Génétiques, Rabat, Morocco
    • ,
  • Seddik Fellat

      Affiliations

    • Ligue Nationale de Lutte Contre les Maladies Cardiovasculaires, Unité d'Etudes des Facteurs Métaboliques et Polymorphismes Génétiques, Rabat, Morocco
    • ,
  • Mohamed Benomar

      Affiliations

    • Ligue Nationale de lutte contre les maladies cardiovasculaires, Service de Cardiologie A, CHU Ibn-Sina, Rabat, Morocco

Received 31 May 2006 ,Revised 12 November 2006 ,Accepted 15 February 2007.

References 

  1. Boushey CJ, Beresford SA, Omenn GS, Motulsky AG. A quantitative assessment of plasma homocysteine as a risk factor for vascular disease. Probable benefits of increasing folic acid intakes. JAMA. 1995;274:1049–1057
  2. Christensen B, Frosst P, Lussier-Cacan S, Selhub J, Goyette P, Rosenblatt DS, et al. Correlation of a common mutation in the methylenetetrahydrofolate reductase gene with plasma homocysteine in patients with premature coronary artery disease. Arterioscler Thromb Vasc Biol. 1997;17:569–573
  3. Graham IM, Daly LE, Refsum HM, Robinson K, Brattström LE, Ueland PM, et al. Plasma homocysteine as a risk factor for vascular disease: the European Concerted Action Project. JAMA. 1997;277:1775–1781
  4. Nygard O, Nordrehaug JE, Refsum H, Ueland PM, Farstad M, Vollset SE. Plasma homocysteine levels and mortality in patients with coronary artery disease. N Engl J Med. 1997;337:230–236
  5. Eikelboom JW, Lonn E, Genest J, Hankey G, Yusuf S. Homocysteine and cardiovascular disease: a critical review of the epidemiologic evidence. Ann Intern Med. 1999;131:363–375
  6. Verhoef P, Stampfer M. Epidemiology of vascular and thrombotic associations. In:  Carmel R,  Jacobsen D editor. Homocysteine in health and disease. Cambridge: Cambridge University Press; 2001;p. 357–370
  7. Ford ES, Smith SJ, Stroup DF, Steinberg KK, Mueller PW, Thacker SB. Homocysteine and cardiovascular disease: a systematic review of the evidence with special emphasis on case-control studies and nested case-control studies. Int J Epidemiol. 2002;31:59–70
  8. Robinson K. Homocysteine and coronary artery disease. In:  Carmel R,  Jacobsen D editor. Homocysteine in health and disease. Cambridge: Cambridge University Press; 2001;p. 371–383
  9. Ueland PM, Refsum H, Beresford SA, Vollset SE. The controversy over homocysteine and cardiovascular risk. Am J Clin Nutr. 2000;72:324–332
  10. Tsai MY, Bignell M, Yang F, Welge BG, Graham KJ, Hanson NQ. Polygenic influence on plasma homocysteine: association of two prevalent mutations, the 844ins68 of cystathionine β-synthase and A2756G of methionine synthase, with lowered plasma homocysteine levels. Atherosclerosis. 2000;149:131–137
  11. Dekou V, Gudnason V, Hawe E, Miller GJ, Stansbie D, Humphries SE. Gene–environment and gene–gene interaction in the determination of plasma homocysteine levels in healthy middle-aged men. Thromb Haemost. 2001;85:67–74
  12. Clayton D, McKeigue PM. Epidemiological methods for studying genes and environmental factors in complex diseases. Lancet. 2001;358:1356–1360
  13. Kraus JP, Oliveriusova J, Sokolova J, Kraus E, Vlcek C, de Franchis R, et al. The human cystathionine β-synthase (CβS) gene: complete sequence, alternative splicing, and polymorphisms. Genomics. 1998;52:312–324
  14. Rozen R. Polymorphisms of folate and cobalamin metabolism. In:  Carmel R,  Jacobsen D editor. Homocysteine in health and disease. Cambridge: Cambridge University Press; 2001;p. 259–269
  15. Boers GH, Smals AG, Trijbels FJ, Fowler B, Bakkeren JA, Schoonderwaldt HC, et al. Heterozygosity for homocystinuria in premature peripheral and cerebral occlusive arterial disease. N Engl J Med. 1985;313:709–715
  16. Clarke R, Daly L, Robinson K, Naughten E, Cahalane S, Fowler B, et al. Hyperhomocysteinemia: an independent risk factor for vascular disease. N Engl J Med. 1991;324:1149–1155
  17. Dekou V, Gudnason V, Hawe E, Miller GJ, Stansbie D, Humphries SE. Gene–environment and gene–gene interaction in the determination of plasma homocysteine levels in healthy middle-aged men. Thromb Haemost. 2001;85:67–74
  18. Nordstrom M, Kjellstrom T. Age dependency of cystathionine beta-synthase activity in human fibroblasts in homocyst(e)inemia and atherosclerotic vascular disease. Atherosclerosis. 1992;94:213–221
  19. Engbersen AM, Franken DG, Boers GH, Stevens EM, Trijbels FJ, Blom HJ. Thermolabile 5,10-methylenetetrahydrofolate reductase as a cause of mild hyperhomocysteinemia. Am J Hum Genet. 1995;56:142–150
  20. Kang SS, Wong PW, Zhou JM, Sora J, Lessick M, Ruggie N, et al. Thermolabile methylenetetrahydrofolate reductase in patients with coronary artery disease. Metabolism. 1988;37:611–613
  21. Kang SS, Zhou J, Wong PW, Kowalisyn J, Strokosch G. Intermediate homocysteinemia: a thermolabile variant of methylenetetrahydrofolate reductase. Am J Hum Genet. 1998;43:414–421
  22. Frosst P, Blom HJ, Milos R, Goyette P, Sheppard CA, Matthews RG, et al. A candidate genetic risk factor for vascular disease: a common mutation in methylenetetrahydrofolate reductase. Nat Genet. 1995;10:111–113
  23. Frantzen F, Faaren AL, Alfheim I, Nordhei AK. An enzyme conversion immunoassay for determining total homocysteine in plasma or serum. Clin Chem. 1998;44:311–316
  24. Weisberg I, Tran P, Christensen B, Sibani S, Rozen R. A second genetic polymorphism in methylenetetrahydrofolate reductase (MTHFR) associated with decreased enzyme activity. Mol Genet Metab. 1998;64:169–172
  25. Chen J, Stampfer MJ, Ma J, Selhub J, Malinow MR, Hennekens CH, et al. Influence of a methionine synthase (D919G) polymorphism on plasma homocysteine and folate levels and relation to risk of myocardial infarction. Atherosclerosis. 2001;154:667–672
  26. Jacques PF, Bostom AG, Selhub J, Rich S, Ellison RC, Eckfeldt JH, et al. National Heart, Lung and Blood Institute, National Institutes of Health. Effects of polymorphisms of methionine synthase and methionine synthase reductase on total plasma homocysteine in the NHLBI family heart study. Atherosclerosis. 2003;166:49–55
  27. Geisel J, Zimbelmann I, Schorr H, Knapp JP, Bodis M, Hübner U, et al. Genetic defects as important factors for moderate hyperhomocysteinemia. Clin Chem Lab Med. 2001;39:698–704
  28. Brouwer DA, Welten HT, Reijngoud DJ, van Doormaal JJ, Muskiet FA. Plasma folic acid cutoff value, derived from its relationship with homocyst(e)ine. Clin Chem. 1998;44:1545–1550
  29. Carvo ML, Camilo ME. Hyperhomocysteinemia is chronic alcohoism: relations to folic acid and vitamins B(6) and B(12) status. Nutrition. 2000;16:296–302
  30. Tsai MY, Welge BG, Hanson NQ, Bignell MK, Vessey J, Schwichtenberg K, et al. Genetic causes of mild hyperhomocysteinemia in patients with premature occlusive coronary artery disease. Atherosclerosis. 1999;143:163–170
  31. Edrisinghe SP. Homocysteine-indiced thrombosis. Br J Biomed Sci. 2004;40–70
  32. Haynes WG. Hyperhomocysteinemia, vascular function and atherosclerosis: effects of vitamins. Cardiovasc Drugs Ther. 2002;16:391–399
  33. Nygard O, Vollset SE, Refsum H, et al. Total plasma homocysteine and cardiovascular risk profile. The Hordaland Homocysteine Study. J Am Med Assoc. 1995;274:1526–1533
  34. O'Callaghan P, Meleady R, Fitzgerald T, Graham I and the European COMAC group. Smoking and plasma homocysteine. Eur Heart J. 2002;23:1580–1586
  35. Bartecci, CE, Mackenzie, TD, Schrier, RW. The human costs of tobacco use. N Engl J Med 1994; 330: (pt1) 907–12, (pt2) 975–80.
  36. Bellamy MF, McDowell IF, Ramsey MW, Brownlee M, Bones C, Newcombe RG, et al. Hyperhomocysteinemia after an oral methionine load acutely impairs endothelial function in adults. Circulation. 1998;98:1848–1852
  37. Nappo F, De Rossa N, Marfella R. Impairement of endothelial function by acute hyper-homocysteinemia and reversal by antioxidant vitamins. JAMA. 1996;281:2113–2118
  38. Tsai JC, Perrella MA, Yoshizumi . Promotion of vascular smooth muscle cell growth by homocysteine: a link to atherosclerosis. Proc Natl Acad Sci U S A. 1994;91:6369–6373
  39. Freyer RH, Wilson BD, Gubler DB, Fitzgerald LA, Rodgers GM. Homocysteine, a risk factor for premature vascular disease and thrombosis, induces tissue factor activity in endothelial cells. Arterioscler Thromb. 1993;13:1327–1333
  40. Palareti G, Salardi S, Piazzi S. Blood coagulation changes in homocystinuria: effects of pyridoxine and other specific therapy. J Pediatr. 1986;109:1001–1006
  41. van der Put NM, Gabreels F, Stevens EMB, Smeitink JA, Trijbels FJ, Eskes TK, et al. A second common mutation in the methylene-tetrahydrofolate reductase gene: an additional risk factor for neural-tube defects?. Am J Hum Genet. 1998;62:1044–1051
  42. Rothenbacher D, Fischer HG, Hoffmeister A, Hoffmann MM, März W, Bode G, et al. Homocysteine and methylenetetrahydrofolate reductase genotype: association with risk of coronary heart disease and relation to inflammatory, hemostatic and lipid parameters. Atherosclerosis. 2002;162:193–200
  43. Song C, Xing D, Tan W, Wei Q, Lin D. Methylenetetrahydrofolate reductase polymorphisms increases risk of esophageal squamous cell carcinoma in a Chinese population. Cancer Res. 2001;61:3272–3275
  44. Castro R, Rivera I, Ravasco P, Jakobs C, Blom HJ, Camilo ME, et al. 5,10-methylenetetrahydrofolate reductase 677C→T and 1298A→C mutations are genetic determinants of elevated homocysteine. Q J Med. 2003;96:297–303
  45. Franco RF, Morelli V, Lourenco D, Maffei FH, Tavella MH, Piccinato CE, et al. A second mutation in the methylenetetrahydrofolate reductase gene and the risk of venous thrombotic disease. Br J Haematol. 1999;105:556–559
  46. Friedman G, Goldschmidt N, Friedlander Y, Ben-Yehuda A, Selhub J, Babaey S, et al. A common mutation A1298C in human methylenetetrahydrofolate reductase gene: association with plasma total homocysteine and folate concentrations. J Nutr. 1999;129:1656–1661
  47. Zetterberg H, Coppala A, D'Angelo A, Palmér M, Rymo L, Blennow . No association between the MTHFR A1298C and transcobalamin C776G genetic polymorphisms and hyper-homocysteinemia in thrombotic disease. Thromb Res. 2003;108:127–131
  48. Friso S, Girelli D, Trabetti E, Stranieri C, Olivieri O, Tinazzi E, et al. A1298C methyleneteetrahydrofolate reductase mutation and coronary artery disease: relationships with C677T polymorphism and homocysteine/folate metabolism. Clin Exp Med. 2002;2:7–12
  49. Zetterberg H, Rymo L, Coppola A, D'Angelo A, Spandidos DA, Blennow K. MTHFR C677T and A1298C polymorphisms and mutated sequences occurring in cis. Eur J Hum Genet. 2002;10:579–582
  50. Szczeklik A, Sanak M, Jankowski M, Dropinski J, Czachor R, Musial J, et al. Mutation A1298C methylenetetrahydrofolate reductase: risk for early coronary disease not associated with hyperhomocysteinemia. Am J Med Genet. 2001;101:36–39
  51. Morita H, Taguchi J, Kurihara H, Kitaoka M, Kaneda H, Kurihara Y, et al. Genetic polymorphism of 5,10 methylenetetrahydrofolate reductase (MTHFR) as a risk factor for coronary artery disease. Circulation. 1997;95:2032–2036
  52. Kluijtmans LA, Young IS, Boreham CA, Murray L, McMaster D, McNulty H, et al. Genetic and nutritional factors contributing to hyperhomocysteinemia in young adults. Blood. 2003;101:2483–2488
  53. Payne DA, Chamoun AJ, Seifert SI, Stouffer GA. MTHFR 677C→T mutation: a predictor of early-onset coronary artery disease. Thromb Res. 2001;103:275–279
  54. Schwahn B, Rozen R. polymorphisms in the methylenetetrahydrofolate reductase gene: clinical consequences. Am J Pharmacogenomics. 2001;1:189–201
  55. van der Put NM, van der Molen EF, Kluijtmans LA, Heil SG, Trijbels JM, Eskes TK, et al. Sequence analysis of the coding region of human methionine synthase: relevance to hyperhomocysteinemia in neural-tube defects and vascular disease. Q J Med. 1997;90:511–517
  56. Wang XL, Duarte N, Cai H, Adachi T, Sim AS, Cranney G. Relationship between total plasma homocysteine, polymorphisms of homocysteine metabolism related enzymes, risk factors and coronary artery disease in the Australian hospital-based population. Atherosclerosis. 1999;146:133–140
  57. Klerk M, Lievers KJ, Kluijtmans LA, Blom HJ, de Heijer M, Schouten EG, et al. The 2756A→G variant in the gene encoding methionine synthase: its relation with plasma homocysteine levels and risk of coronary heart disease in a Dutch case-control study. Thromb Res. 2003;110:87–91
  58. Hyndman ME, Bridge PJ, Warnica JW, Fick G, Parsons HG. Effect of heterozygosity for the methionine synthase 2756A→G mutation on the risk for recurrent cardiovascular events. Am J Cardiol. 2000;86:1144–1146
  59. Wang XL, Cai H, Cranney G, Wilcken DE. The frequency of a common mutation of the methionine synthase gene in the Australian population and its relation to smoking and coronary artery disease. J Cardiovasc Risk. 1998;5:289–295
  60. Harmon DL, Shields DC, Woodside JV, McMaster D, Yarnell JW, Young IS, et al. Methionine synthase D919G polymorphism is a significant but modest determinant of circulating homocysteine concentrations. Genet Epidemiol. 1999;17:298–309
  61. D'Angelo A, Coppola A, Madonna P, Fermo I, Pagano A, Mazzola G, et al. The role of vitamin B12 in fasting hyper-homocysteinemia and its interaction with the homozygous C677T mutation of the MTHFR gene. A case-control study of patients with early-onset thrombotic events. Thromb Haemost. 2000;83:563–570
  62. Morita H, Kurihara H, Sugiyama T, Sugiyama T, Hamada C, Sakai E, et al. Polymorphism of the methionine synthase gene: association with homocysteine metabolism and late-onset vascular diseases in the Japanese population. Arterioscler Thromb Vasc Biol. 1999;19:298–302
  63. Wilson A, Platt R, Wu Q, Leclerc D, Christensen B, Yang H, et al. A common variant in methionine synthase reductase combined with low cobalamin increases risk for spina bifida. Mol Genet Metab. 1999;67:317–323
  64. Leclerc D, Wilson A, Dumas R, Gafuik C, Song D, Watkins D, et al. Cloning and mapping of a cDNA for methionine synthase reductase, a flavoprotein defective in patients with homocystinuria. Proc Natl Acad Sci U S A. 1998;95:3059–3064
  65. Zavadakova P, Sokolova J, Kozich V. Identification of novel polymorphisms and analysis of haplotypes in the methionine synthase reductase gene [abstract]. J Inherit Metab Dis. 2003;26:36
  66. Feix A, Winkelmayer WC, Eberle C, Sunder-Plassmann G, Födinger M. Methionine synthase reductase MTRR 66A→G has no effect on total homocysteine, folate, and vitamin B12 concentrations in renal transplant patients. Atherosclerosis. 2004;174:43–48
  67. Geisel J, Zimbelmann I, Schorr H, Knapp JP, Bodis M, Hübner U, et al. Genetic defects as important factors for moderate hyperhomocysteinemia. Clin Chem Lab Med. 2001;39:698–704
  68. Brown CA, McKinney KQ, Kaufman JS, Gravel RA, Rozen R. A common polymorphism in methionine synthase reductase increases risk of premature coronary artery disease. J Cardiovasc Risk. 2000;7:197–200
  69. Ray JG, Langman LJ, Vermeulen MJ, Evrovski J, Yeo EL, Cole DEC. Genetics University of Toronto Thrombophilia Study in Women (GUTTSI): genetic and other risk factors for venous thromboembolism in women. Curr Control Trials Cardiovasc Med. 2001;2:141–149
  70. Jacques PF, Rosenberg IH, Rogers G, Selhub J, Bowman BA, Gunter EW, et al. Serum total homocysteine concentrations in adolescent and adult Americans: results from the third National Health and Nutrition Examination Survey. Am J Clin Nutr. 1999;69:482–489
  71. Hobbs CA, Sherman SL, Yi P, Hopkins SE, Torfs CP, Hine RJ, et al. Polymorphisms in genes involved in folate metabolism as maternal risk factors for Down syndrome. Am J Hum Genet. 2000;67:623

PII: S0953-6205(07)00151-3

doi: 10.1016/j.ejim.2007.02.020

European Journal of Internal Medicine
Volume 18, Issue 6 , Pages 474-483 , October 2007

Article Tools